Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 67.1%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 57,300 shares, a decrease of 67.1% from the January 31st total of 174,100 shares. Approximately 7.7% of the company’s stock are short sold. Based on an average daily volume of 148,900 shares, the short-interest ratio is presently 0.4 days.

Windtree Therapeutics Price Performance

Shares of NASDAQ:WINT opened at $3.18 on Friday. The company has a market capitalization of $2.38 million, a PE ratio of -0.19 and a beta of 0.53. Windtree Therapeutics has a 1 year low of $3.12 and a 1 year high of $737.43. The business has a fifty day moving average price of $9.80 and a two-hundred day moving average price of $88.75.

Institutional Trading of Windtree Therapeutics

An institutional investor recently bought a new position in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 29.33% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating and set a $350.00 target price on shares of Windtree Therapeutics in a research report on Wednesday, December 4th.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.